跳到正文
← 返回论文列表与筛选
阅读说明

本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。

DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。

引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。

关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。

分类依据与纠错

AI 根据所提供的论文材料归类:摘要聚焦临床基因组整合与贝叶斯变量选择,未提供因果识别或其他所列经济计量方向的充分依据。

反馈分类问题

正在核对关联版本…

代码、数据与补充材料

正在核对对应版本的资源…

关注这篇论文的作者

高维多平台临床基因组数据的功能整合贝叶斯分析

研究问题
如何从多平台临床基因组数据中识别生物标记物的上游功能证据,并将其纳入变量选择以增强疾病相关信号检测?
方法与思路
作者提出 fiBAG,以高斯过程模型结合贝叶斯因子量化可能非线性的功能证据,再将证据映射为校准的尖峰厚尾先验。
材料陈述的贡献
摘要称,功能校准的整合方法在模拟中比非整合方法具有更高检测功效,并在十四类癌症中分析与癌症干性及生存相关的标记物。
阅读关注点
应核对功能证据如何量化、贝叶斯因子向先验的校准规则,以及变量选择的评价标准和患者结局关联的解释边界。
阅读边界
仅据 OpenAlex 索引摘要,稿件版本未注明;模拟条件与具体结果未说明,功能证据和结局关联不能据此确认为因果机制或临床效果。

原文摘要

Rapid advancements in collection and dissemination of multi-platform molecular and genomics data has resulted in enormous opportunities to aggregate such data in order to understand, prevent, and treat human diseases. While significant improvements have been made in multi-omic data integration methods to discover biological markers and mechanisms underlying both prognosis and treatment, the precise cellular functions governing these complex mechanisms still need detailed and data-driven de-novo evaluations. We propose a framework called Functional Integrative Bayesian Analysis of High-dimensional Multiplatform Genomic Data (fiBAG), that allows simultaneous identification of upstream functional evidence of proteogenomic biomarkers and the incorporation of such knowledge in Bayesian variable selection models to improve signal detection. fiBAG employs a conflation of Gaussian process models to quantify (possibly non-linear) functional evidence via Bayes factors, which are then mapped to a novel calibrated spike-and-slab prior, thus guiding selection and providing functional relevance to the associations with patient outcomes. Using simulations, we illustrate how integrative methods with functional calibration have higher power to detect disease related markers than non-integrative approaches. We demonstrate the profitability of fiBAG via a pan-cancer analysis of 14 cancer types to identify and assess the cellular mechanisms of proteogenomic markers associated with cancer stemness and patient survival.

笔记与分组
相关领域论文